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http://dx.doi.org/10.1016/j.cell.2015.05.023Small-molecule probes can illuminate biological processes and aid in the assessment of emerging
therapeutic targets by perturbing biological systems in a manner distinct from other experimental
approaches. Despite the tremendous promise of chemical tools for investigating biology and dis-
ease, small-molecule probes were unavailable for most targets and pathways as recently as a
decade ago. In 2005, the NIH launched the decade-longMolecular Libraries Programwith the intent
of innovating in and broadening access to small-molecule science. This Perspective describes
how novel small-molecule probes identified through the program are enabling the exploration of1252 Cell 161, June 4, 2015 ª2015 Elsevier Inc.
biological pathways and therapeutic hypotheses not otherwise testable. These experiences
illustrate how small-molecule probes can help bridge the chasm between biological research
and the development ofmedicines but also highlight the need to innovate the science of therapeutic
discovery.Introduction
Despite remarkable advances in chemistry and biology, small-
molecule drug discovery remains a slow, costly, and low-yielding
activity. In fact, productivity in drug discovery has fallen in
recent years. It is estimated that only about one in ten drug can-
didates entering the clinic are eventually approved—despite
increasing investment (Hay et al., 2014). A prime hurdle is our
inability to predict the physiologic consequences of modulating
candidate drug targets in humans. Currently, lack of sufficient
efficacy is the cause of clinical candidates failing in about 50%
of Phase II trials (Arrowsmith, 2011a) and 66% of Phase III trials
(Arrowsmith, 2011b). This high rate of attrition results from an
inadequate understanding of how diseases are caused and
maintained in human populations.
Expectations regarding the therapeutic relevance of a target
are often based on inferences from experiments that alter nucleic
acids encoding the putative target (e.g., deleting a DNA seq-
uence; degrading or overexpressing an RNA sequence). Yet
most small-molecule drugs alter the functions of proteins, and
the correlation between perturbing nucleic acids and their
encoded proteins is imperfect. Modulating the functions of
candidate drug targets with small molecules would provide in-
sights with far greater relevance to drug discovery. However,
the current absence of effective small-molecule probes or
‘‘tool compounds’’ for the vast majority of proteins limits a sys-
tematic application of this approach to target validation.
Advances in understanding human biology, particularly
‘‘experiments of nature’’ revealed with increasing frequency by
human genetics, are now shining a light on many complex dis-
eases and pointing to targets with a much higher likelihood of
providing a therapeutic benefit safely than those derived from
model systems (Plenge et al., 2013). And the increasing availabil-
ity of patient-derived cells and advances in precise genome-
editing methods are providing more effective model systems
for investigating the functional impact of observed human ge-
netic variation.
But these insights also create a demand for small-molecule
probes. The therapeutic implications of these genetic alterations
are intriguing, but not certain. Not only do they raise the ‘‘gene
versus protein’’ issue above—they often reflect heritable modu-
lations from birth, so the effect of targeting an implicated protein
by a therapeutic in an ongoing disease is uncertain. Also, the
therapeutic strategies suggested by these studies frequently
point to targets that are inaccessible to protein-based drugs
and for which small-molecule modulators are currently non-
existent—targets that fall outside traditional drug classes and
have been labeled ‘‘undruggable’’ by some within the pharma-
ceutical and academic communities. There is an urgent need
to innovate chemistry and chemical biology in ways that enable
small-moleculemodulation of the challenging targets at the heart
of disease.In 2005, in an effort to bridge the chasm between basic bio-
logical research and the medicines that should in principle
derive from insights into disease, the NIH initiated the
decade-long Molecular Libraries Program (MLP) (Austin et al.,
2004). At that time, small-molecule discovery techniques,
including high-throughput screening (HTS) and medicinal
chemistry expertise, existed predominantly within pharmaceu-
tical companies. Following a 3-year pilot phase, the MLP
launched the Molecular Libraries Probe Production Centers
Network (MLPCN), which comprised Comprehensive Screening
Centers, Specialized Screening Centers and Specialized
Chemistry Centers (Figure 1). These centers were among the
earliest efforts to bring systematic small-molecule screening
into academic settings.
The MLP was designed as an experiment in integrating big
science and individual investigator-led science. Individual inves-
tigators submitted funding applications to the NIH for assay
development or screening projects. For screening projects that
were selected through peer review, MLP Centers conducted
high-throughput screens using an MLP small-molecule library
that grew over the course of the program to a final size of
about 390,000 compounds. Novel compounds emerging from
the academic synthetic chemistry community, for instance
small, chiral compounds having novel skeletons derived from
diversity-oriented synthesis (DOS) and other compounds
derived from the NIH-funded Chemical Methodologies and
Library Development (CMLD) program, made up about 5% of
the compound library and yielded small-molecule probes,
including some highlighted below, that would not have been
discovered otherwise. Following on the screens, the MLP pur-
sued chemical optimization of hits with the aim of identifying
small-molecule probes, including ones targeting proteins viewed
as challenging, with sufficient potency and selectivity to provide
‘‘high-quality’’ tool compounds (Frye, 2010; Oprea et al., 2009;
Workman and Collins, 2010). These probes were envisioned as
a first step toward the testing of novel biological and therapeutic
hypotheses.
With the conclusion of the program, we can now look back
at the progress achieved over the decade of the MLP and
forward at how to benefit from the lessons learned. We
summarize advances in discovering biologically active small
molecules and illustrate how these advances are yielding a
rich armamentarium of novel small-molecule probes and,
perhaps most notably, experimental paths to therapeutics dis-
covery. The series of ‘‘vignettes’’ described here provide
examples of methodological development and small-molecule
probe discovery that is enabling the testing of specific
therapeutic hypotheses. These examples highlight the impor-
tance of small-molecule probes as critical tools for accelerating
translational research but also emphasize the tremendous
hurdles that remain to be cleared if we are to capitalize fullyCell 161, June 4, 2015 ª2015 Elsevier Inc. 1253
Figure 1. Centers Comprising the MLPCN
Networkon the rapid pace of biological advances to improve human
health. If the lack of productivity of therapeutics discovery is
to be reversed, transformative innovation will be needed to
push back barriers at every stage of small-molecule therapeu-
tics discovery.
Bridging the Chasm
The most visible output of the MLP is a set of 375 small-
molecule probes for exploring biology. MLP probes cover a
diverse spectrum of target classes, including well-investigated
classes such as kinases and G protein-coupled receptors
(GPCRs) and less frequently investigated classes such as
GTPases, proteases, and RNA-binding proteins (Figure 2).
This broad coverage of target space highlights the intentional
focus of the MLP Network on relatively under-explored pro-
teins. Many of these compounds were ‘‘first-in-class’’ probes
that provided initial evidence for the chemical tractability of
a previously recalcitrant target or that modulated a target
by a distinct mechanism from previous small molecules
(Figure S1).
Perhaps themost exciting outcome of theMLPwas the impact
of probe-discovery efforts in highlighting paths for therapeutics
discovery. Here, we describe a number of vignettes that illustrate
the breadth of the translational impact of small-molecule probes
identified through MLP research. These vignettes highlight ad-
vances in small-molecule science, as well as insights gained
through the use of small-molecule probes in diverse disease
contexts. Many of these and other MLP projects have directly
catalyzed efforts to translate emerging biomedical insights
(Table 1).
Targeting Poorly Characterized Enzymes
Small-molecule probes can aid efforts to annotate the function
of poorly characterized enzymes, including those that human
genetic studies have implicated in disease. However, it is
difficult to establish a typical biochemical high-throughput
screening assay to identify modulators of an enzyme if the
substrate is not known. Activity-based protein profiling
(ABPP) makes use of reactive small-molecule ligands to label1254 Cell 161, June 4, 2015 ª2015 Elsevier Inc.covalently the active sites of members
of large enzyme families, including those
that are uncharacterized (Nomura et al.,
2010). In this approach, broadly reactive
ABPP probes can be used in a competi-
tion experiment to identify small mole-
cules that selectively reduce labeling of
a desired enzyme target. Despite the
potential, this substrate-free screening
approach has not been widely used
because the current competitive ABPP
methods relies on SDS-PAGE or mass
spectrometry assays and can only be
used to evaluate, at most, a few hundred
compounds.The MLP undertook a project to develop a high-throughput
fluorescence polarization technology for ABPP-based screen-
ing (fluopol-ABPP) (Bachovchin et al., 2009). A small fluoro-
phore in solution rotates rapidly and emits a low fluorescence
polarization signal, whereas a fluorophore bound to a protein
rotates more slowly and emits a higher signal. Based on this
known property, an ABPP assay was developed in which
fluorescent ABPP probe labeling of an enzyme target generates
a signal that is then reduced when a small-molecule ‘‘hit’’ effec-
tively competes for binding. This approach proved generally
applicable to high-throughput screening in multi-well format.
For instance, screening 20,000 small molecules in 384-well
plates led to the identification of multiple small molecules
that blocked serine fluorophosphonate (FP)-rhodamine labeling
of the serine hydrolase retinoblastoma-binding protein-9
(RBBP9), a cancer-associated enzyme. Secondary chemopro-
teomic assays in mouse brain fractions and human cell
lysates subsequently identified the natural product emetine
(ML081; Figure 3) as the first RBBP9 inhibitor that is selective
for this serine hydrolase family member (Bachovchin et al.,
2009).
Small-molecule inhibitors of protein phosphatase methyles-
terase-1 PME-1, a regulator of protein phosphatase 2A (PP2A)
that has been linked to cancer and neurodegeneration, had not
previously been identified, in part due to the challenges of
designing an in vitro biochemical assay suitable for monitoring
the carboxymethylation state of PP2A. A fluopol-ABPP screen
yielded initial hits, from which four novel aza-b-lactams were
shown in follow-up assays to selectively inhibit PME-1 in human
cells. The most potent inhibitor, ML174 (ABL127; Figure 3), in-
hibited PME-1 with a low nanomolar IC50 and had no activity
against more than 50 other serine hydrolases. In mice, ML174
selectively inactivated PME-1 and increased the levels of PP2A
carboxymethylation in the brain (Bachovchin et al., 2011). Strik-
ingly, the aza-b-lactam hits are examples of innovations resulting
from diversity synthesis performed by an academic chemistry
laboratory—such compounds are distinct from conventional
screening compounds available from vendors. The aza-b-lactam
Figure 2. Spectrum of Targets Modulated
by MLP Probes
Target classes modulated by MLP probes are
visualized based on HTS data and user-defined
thresholds. Arc lengths represent the number of
distinct targets within a target class that are
modulated by this collection of probes. This graph
was generated using the BioAssay Research
Database (BARD; bard.nih.gov), which was
generated by the MLP to enable users to mine and
visualize small-molecule activity data. The graph
depicts the bioactivity of about 65% of the total
number of MLP probes across 415 unique assays
associated with 460 targets, which were catego-
rized using the Panther database into 110 protein
categories. The breadth of target classes high-
lights the diverse biology and target space
explored by the MLP.scaffold has subsequently proven to be a versatile chemotype
for developing selective serine hydrolase inhibitors (Zuhl et al.,
2012).
TheMLPhasalso developedamodifiedABPPmethod that can
be used to read out cellular and in vivo target engagement, an
often-missing link in the preclinical development of drug leads
(Simon et al., 2013). Using fluopol-ABPP, the first selective inhib-
itors of the serine hydrolases lysophospholipase 1 (LYPLA1) and
lysophospholipase 2 (LYPLA2) were identified and found to act
reversibly. For reversible inhibitors that lack known biomarkers
such as endogenous substrates or products, demonstrating
target engagement is challenging. To overcome this limitation,
new ABPP probes were designed that reacted with serine hydro-
lasesover anobservable timewindow. In humancells and inmice,
these moderately reactive ABPP probes could be used to accu-Cell 1rately measure the target engagement
and selectivity of the LYPLA1 and LYPA2
inhibitors. For instance, dosing mice with
the inhibitors blocked more than 90% of
LYPLA1 and LYPA2 activity in lung, heart,
and kidney tissue, whereas the activity of
the enzymes was only reduced by about
50% in the brain and no detectable
enzyme inhibition was seen in the liver
(Adibekian et al., 2012).
More generally, fluopol-ABPP has
proven useful for enzyme classes beyond
serine hydrolases and has been used for
screening glutathione S-transferases
(Tsuboi et al., 2011), arginine methyl-
transferases (Dillon et al., 2012), and pro-
tein arginine deiminases (Knuckley et al.,
2010).
Toward Novel Mechanisms of
Action Compounds through
Multiplexed Bioactivity Data
Identifying small-molecule probes that
modulate challenging targets often re-
quires accessing new chemical starting
points. Previous efforts to address this
gap have typically focused on increasingdiversity from a chemical structure perspective, a metric known
to predict imperfectly the identity of compounds with new bioac-
tivities. The MLP worked to develop high-throughput and
inexpensive methods that would enable multiplexed cellular
bioactivity measurements to guide directly the building of com-
pound collections whose members have novel mechanisms of
action.
Gene-expression studies have demonstrated the impact of
unbiased, high-dimensional profiling data in defining disease
states and also in inferring compound mechanism of action
(Hughes et al., 2000; Lamb et al., 2006; Weinstein et al., 1997).
High-content imaging could provide a complementary mea-
surement for capturing complex disease phenotypes in unbi-
ased, high-throughput formats. However, current high-content
screening assays have either focused on a specific cellular61, June 4, 2015 ª2015 Elsevier Inc. 1255
Table 1. Translational Trajectory for MLP Probes
Targets MLP Probes Post-MLP Trajectory
Serine hydrolases ML081, ML174, ML211, ML225,
ML226, ML256, ML257, ML294,
ML295, ML296
Screening and assay platforms, serine hydrolase-directed small-molecule libraries,
and serine hydrolase inhibitors, resulting in part from MLP projects, have been licensed
to Abide Therapeutics, which is pursuing the further identification, preclinical, and
clinical development of serine hydrolase inhibitors for a variety of indications, in
particular neurological, immunological, and metabolic diseases.
P. falciparum, T. cruzi ML238, ML341 The identification of the MLP malaria probe led to a Gates Foundation-funded Chemical
Diversity Initiative that has explored the use of the DOS collections more broadly in
infectious disease and has yielded promising compounds that target the etiological
agents of malaria and tuberculosis via novel mechanisms. In work supported by the
Global Health Innovation Technology (GHIT) fund and in collaboration with Eisai, the MLP
anti-trypanosomal probe is being optimized to enable in vivo proof of concept studies
and a DOS-based anti-malarial agent is being optimized toward IND-enabling studies.
S1P1 agonists ML007 Receptos licensed intellectual property surrounding S1P1 agonists including the
racemate of its clinical candidate RPC1063, which is currently in two Phase III studies
in relapsing multiple sclerosis and about to enter Phase III testing in ulcerative colitis
and Phase II testing in Crohn disease.
M4 mAChR ML108, ML253 AstraZeneca has licensed intellectual property associated with the M4 PAMs, and
the company is pursuing preclinical development of the compounds as a potential
treatment for the neuropsychiatric symptoms associated with AD and schizophrenia.
GCase ML198 This probe and related analogs have been licensed to Lysosomal Therapeutics,
which is pursuing preclinical development of these non-inhibitory GCase chaperones.
Integrin aIIbb3
receptor antagonist
ML165 Rockefeller University and NCATS are pursuing an IND based on a derivative of ML165
indicated for pre-hospital therapy of patients with ST segment elevated myocardial
infarction (STEMI).
P97 AAA ATPase
inhibitor
ML240 Cleave BioSciences licensed intellectual property surrounding ML240. A derivative of
this probe, CB-5083, is currently in two Phase I studies, one in relapsed and refractory
multiple myeloma and the other in solid tumors refractory to the standard-of-care.process of interest or a limited set of cellular readouts, often
based on labeled proteins or qPCR of target transcripts, or
have been limited in throughput (Loo et al., 2007; Weinstein
et al., 1997; Young et al., 2008). The MLP therefore focused on
a ‘‘cell-painting assay’’ that enables a more unbiased approach
for characterizing alterations induced by disease states or small-
molecule perturbagens (Gustafsdottir et al., 2013). Using six
dyes measured across five channels, 824 distinct cellular
morphological features could be quantitatively imaged. In a pilot
assay, small molecules known to have similar bioactivities were
accurately clustered together based on similarities between im-
age-based profiles. As cell morphology is impacted by many
factors ranging from genetic and epigenetic to metabolic and
environmental, we anticipate that the low cost, but high-dimen-
sional imaging assay will facilitate identification of unexpected
cellular alterations associated with small-molecule perturbations
and disease.
While methods such as gene-expression profiling and the new
image-based profiling assay contain rich information describing
biological responses to small molecules, few approaches are
available to use these data to understand structure-activity rela-
tionships (SAR). To enable more effective multi-parameter opti-
mization of probes and therapeutic leads, the MLP developed
a computational method to generate SAR information auto-
matically from high-dimensional small-molecule profiling data
(Wawer et al., 2014a). Gene expression profiling data and cell-
painting data were collected for about 20,000 DOS molecules1256 Cell 161, June 4, 2015 ª2015 Elsevier Inc.and just over 2,000 bioactive compounds. Association-rule
mining was then used to define ‘‘rules’’ of varying strengths
that connected chemical attributes (e.g., contiguous substruc-
tures within compounds, shared synthetic histories) to biological
effect patterns in the gene expression and imaging data. In one
application of the methodology, identification of a DOS-based
molecule that co-clustered with structurally unrelated microtu-
bule destabilizers provided an opportunity for ‘‘scaffold hop-
ping’’ based on the signatures derived from this high-content
information.
Rooted in these methodological advances, the question
became whether multiplexed cellular small-molecule activity
data could be used to create a screening library with maximal
bioactivity (performance) diversity. There is general consensus
that a small-molecule library that perturbs as many biological
targets and induces as many distinct cellular phenotypes
as possible would be most effective for cell-based screening.
However, the data needed to create a priori such a screening
collection were not previously available. As a consequence,
assembling diverse screening collections has thus far focused
primarily on the computed diversity of chemical structures. In
one notable recent paper, a retrospective analysis of high-
throughput screening data was used to assemble a library on
the basis of biological activity (Petrone et al., 2012); however,
this method, which is based on analysis of historical data, is
not extensible to new candidate library members. The MLP
measured gene-expression and image-based profiles for over
Figure 3. MLP Probes Highlighted in
Vignettes12,000 bioactive compounds and over 17,000 diversity-oriented
synthesis (DOS)-based molecules for which HTS results from up
to 178 cell-based screens were available (Wawer et al., 2014b).
We asked if the profiling data could select for compounds with
diverse bioactivities, as judged by comparing patterns of
activity in cells or against target proteins. Compounds selected
based on varied activity in the imaging and gene expression
assay profiles significantly outperformed compounds selected
randomly or based on chemical diversity when their performance
diversity in historical HTS assays was compared. In addition, we
discovered thousands of compounds, many of which formed
scaffold-based clusters that induced cell morphology and
gene expression patterns not seen within the 12,000 bioactives,
likely hinting at novel mechanisms of action. These methods and
others that yield multiplexed data reporting complementaryCell 1measures of compound activity offer a
powerful route for prioritizing the synthe-
sis and testing of small molecules more
likely to modulate novel therapeutic
targets.
New Anti-infectives through
Chemical Diversity
Many neglected infectious diseases are
endemic to developing nations, and the
socioeconomic impact of these diseases
is devastating. The impact of drug resis-
tance and the lack of effective drugs are
well exemplified by malaria and Chagas
disease, respectively. In the case of ma-
laria, there are several drugs available for
treatment, but rapid emergence of resis-
tant parasites poses a serious problem
(Fidock, 2013). The currently available
treatment options for Chagas disease
are very limited and are efficacious only
during the acute phase of the disease,
not the chronic phase. Moreover, the se-
vere adverse effects of the current anti-
Chagas drugs lead to poor patient
compliance (Bern, 2011). The develop-
ment of safe new drugs for treating ma-
laria and Chagas and other infectious
diseases is urgently needed.
Identifying anti-malarials and anti-try-
panosomal agents with novel chemical
structures and mechanisms of action
may facilitate the development of thera-
pies that are effective against parasites
resistant to current drugs. DOS pathways
have proven highly effective at rapidly
generating novel, stereochemically rich
compounds, including ones containing
8- to 14-membered rings (Gerard et al.,2011; Lowe et al., 2012; Marcaurelle et al., 2010), and the MLP
screening library contained more than 5,000 DOS compounds
in this vein. These compounds, in conjunction with certain MLP
probe-discovery projects that used a larger collection of
100,000 DOS compounds, have enabled the identification of
small-molecule probes that act against these infectious agents
through new mechanisms.
A cell-based malaria viability screen using an 8,000 DOS com-
pounds led to the identification of a highly active hit with four
stereogenic elements. Of the 15 other possible stereoisomers
of the molecule that were present in the screening collection,
only one had any detectable activity. Subsequent optimization,
guided by these stereochemical insights, led to the identification
of ML238 (Figure 3), which is potent against both the chloro-
quine-resistant Dd2 strain (IC50 = 0.4 nM) and the wild-type61, June 4, 2015 ª2015 Elsevier Inc. 1257
3d7 strain (IC50 = 0.6 nM) of Plasmodium falciparum (Heide-
brecht et al., 2012; Weiwer et al., 2010). In addition, ML238
has good water solubility and does not lyse red blood cells
(EC50 > 40,000 nM), which is important because it suggests a
lack of broad cytotoxicity. To determine the compound’s
mechanism of action, MLP generated ML238-resistant parasites
and conducted whole-genome sequencing. These studies re-
vealed that ML238 acts at the quinone reductase site of the
bc1 complex (Q1) (Lukens et al., 2015), which is on the opposite
side of the cell membrane from the quinol oxidase site targeted
by the anti-malarial drug atovaquone. ML238 and atovaquone
lacked cross-resistance and were synergistic in combination,
highlighting the quinone reductase site as an anti-malarial thera-
peutic target that may overcome atovaquone resistance (Lukens
et al., 2015).
Similarly, a cell-based screen for molecules with selective
lethality against Trypanosoma cruzi, the etiological agent of Cha-
gas disease, identified ML341 (Figure 3), a DOS-derived small-
molecule probe (Carmody et al., 2010; Dandapani et al., 2014).
ML341 is potent against several strains of T. cruzi, including
the clinical cardiotropic isolate CA-1 strain, clone 72 (CA-I/72)
(IC50 = 1 nM). Next, ML341was evaluated for in vitro cidal activity
against a CA-I/72 strain in bovine skeletal muscle (BESM) cells.
Emergence of the trypomastigote form of T. cruziwasmonitored
daily in infected BESM cells treated withML341 or benznidazole,
the current first line drug. In this stringent assay, ML341 was
cidal at 40 nM, whereas benznidazole was cidal only at
6.6 mM. In addition to this potency, ML341 was stable to mouse
liver microsomes, which may facilitate the use of this probe in
in vivo studies. Out of the eight possible stereoisomers of
ML341, only two stereoisomers were stable to mouse liver
microsomes, a finding that helped guide further medicinal chem-
istry optimization. As seen in these two examples, having a
comprehensive set of stereoisomers in the screening collection
was crucial for evaluating rapidly stereochemistry-based SAR
for potency and ancillary pharmacology.
Sphingosine-1-Phosphate Receptor Modulators
Characterizing the mechanisms of action behind the anti-in-
flammatory properties of FTY720, a derivative of the fungal
metabolite-derived serine palmityoltransferase inhibitor myrio-
cin (Chen et al., 1999), led to the discovery that FTY720 mod-
ulates sphingosine-1-phosphate (S1P) receptors to regulate
lymphocyte tracking (Mandala et al., 2002). This finding then
paved the way for the subsequent clinical development of
FTY720 (fingolimod), a sphingosine analog that modulates
four of the five human S1P receptors, for the treatment of mul-
tiple sclerosis (Rosen et al., 2008). S1P receptors are ex-
pressed predominantly in immune, neural, endothelial, and
smooth muscles cells and are believed to play roles that
include regulating immune cell trafficking, endothelial barrier
integrity, and blood pressure, suggesting the potential to
modulate specific receptor subtypes to treat a variety of dis-
eases (Rosen et al., 2013).
To better validate individual S1P receptors as therapeutic
targets, the MLP set out to identify small-molecule probes
that selectively agonized or antagonized each receptor. A se-
lective S1P1 antagonist (ML056, Figure 3) with in vivo activity
was developed through rational synthesis and used to explore1258 Cell 161, June 4, 2015 ª2015 Elsevier Inc.the impact of perturbing this receptor on lymphocyte move-
ment and function, providing evidence that the therapeutic ef-
fects of FTY720 are primarily mediated through this receptor
(Sanna et al., 2006). The concomitant reduction in lympho-
cytes by the antagonist, resulting in endothelial leakage and
severe pulmonary edema, showed that agonist therapy was
the only tolerable choice for autoimmune disease (Rosen
et al., 2013).
The poor water solubility of ML056 imparted by a hydrophobic
strong zwitterion could be overcome both in vitro and in vivo by
formulation as the reversible carbonate adduct. This derivatiza-
tion was essential for the maintenance of complete receptor oc-
cupancy of stable S1PR1, which enabled the first successful
crystal structure of a lipid-sensing GPCR (Hanson et al., 2012).
When combined with biochemical studies, the S1P1 structure
also provided insights into a new agonist-binding mode used
by compounds that include the second-generation S1P1 agonist
ML007 (Figure 3). This series, identified in an allosteric agonist
primary screen, was determined in a secondary assay to be
subject to non-competitive inhibition by ML056, an orthosteric
agonist, occupying the same site as the receptor’s endogenous
ligand. These studies defined a binding pocket distinct from S1P
that affords greater receptor selectivity and potentially a better
pharmacokinetic profile and therapeutic index (Gonzalez-Cab-
rera et al., 2008).
Agonizing the S1P1 receptor to modulate immune cell traf-
ficking may provide a therapeutic approach for diseases beyond
multiple sclerosis. Clinical outcomes following influenza infection
are determined by properties instrinsic to the virus strain and
also differences in the host immune response. In particular,
high cytokine levels and immune cell recruitment correlate with
a poor outcome. In mice infected with a 2009 H1N1 pandemic
influenza viral isolate, CYM-5442, an optimized derivative of
ML007 with in vivo activity, inhibited the secretion of cytokines,
reduced immune cell infiltration into the lung, and improved sur-
vival—while having no impact on viral titers (Teijaro et al., 2011;
Walsh et al., 2011).
The MLP has also identified agonists of the S1P2 (ML031;
Figure 3) (Satsu et al., 2013), S1P3 (ML249; Figure 3) (Guerrero
et al., 2010a; Jo et al., 2012; Urbano et al., 2013), and S1P4
(ML248; Figure 3) (Guerrero et al., 2010b; Guerrero et al., 2012)
receptors, as well as an S1P4 receptor antagonist (ML131;
Figure 3) (Guerrero et al., 2011; Oldstone et al., 2010; Urbano
et al., 2011a; Urbano et al., 2011b), providing multiple first-in-
class small-molecule probes for further elucidating the functions
of this class of GPCRs. ML249, an allosteric agonist for the
S1P receptor has been used to define orthosteric, allosteric,
and biopic space within the S1P3 receptor-binding pocket (Jo
et al., 2012).
Antagonists of PPARg Phosphorylation
The thiazolidinedione (TZD) class of anti-diabetic drugs com-
prises PPARg agonists that increase expression of the insulin-
sensitizing hormone adiponectin and decrease expression of
insulin resistance-inducing hormones—in part contributing to
their potent insulin-sensitizing efficacy (Yu et al., 2002). Although
drugs in this class are marketed to treat type-2 diabetes, their
clinical utility has been limited by serious side effects seen in
a minority of patients, including fluid retention (Staels, 2005),
congestive heart failure (Nesto et al., 2003), and decreased bone
density (Aubert et al., 2010).
The anti-diabetic efficacy of these drugs was long thought to
result from receptor agonism. Strikingly though, as additional
PPARg modulators were developed, drug efficacy correlated
more tightly with ligand-binding affinity than with agonist activ-
ity, prompting a closer examination of the mechanism through
which PPARg ligands improve insulin sensitization. PPARg
ligands that were potent insulin sensitizers were found to be
highly effective at reducing obesity-induced phosphorylation of
PPARg at S273 in mice, despite varying levels of receptor ago-
nism. Also, the therapeutic efficacy of the TZD rosiglitazone
correlated with how effectively the drug reduced PPARg phos-
phorylation at S273 in individual patients. Expression profiling
in adipocytes revealed that phosphorylation of PPARg at S273
leads to repression of a subset of target genes associated
with obesity and insulin sensitivity (Choi et al., 2010). Recent
studies have further shown that docking of the transcriptional
repressor Thrap3 to phospho-S273 on PPARg regulates the
expression of diabetes-associated genes (Choi et al., 2014).
Collectively these results suggest that blocking phosphorylation
of PPARg at S273, by normalizing expression of insulin sensi-
tizing genes, is the dominant therapeutic mechanism of this
drug class. However, it was not clear if small molecules could
be identified that sufficiently separated the two activities of
TZDs and, if found, what the efficacy and safety profile of
such compounds would be.
Starting from known potent partial agonists of PPARg, the
MLP synthesized and tested analogs to look for molecules that
bind the receptor tightly and inhibit phosphorylation of S273
but are devoid of receptor agonist activity. Identifying small mol-
ecules that block a post-translational modification of a receptor
is a challenging objective that was aided by a toolbox ofmethods
developed by the MLP for characterizing nuclear receptor struc-
ture-function (Marciano et al., 2014a). These efforts led to the
non-agonist (antagonist) probe ML244 (SR1664; Figure 3) (Choi
et al., 2011; Kamenecka et al., 2010). Hydrogen-deuterium
exchange (HDX), which has proven particularly effective for char-
acterizing ligand-induced conformational dynamics of nuclear
receptors (Marciano et al., 2014b), revealed that ML244 directly
binds PPARg, does not stabilize the Af2 surface of the receptor
that is known to drive classical agonism, yet perturbs the surface
of the ligand-binding domain to induce a conformation that is not
susceptible to phosphorylation of S273. Importantly, because
ML244 binds PPARg rather than directly inhibiting Cdk5, a
kinase that mediates S273 phosphorylation of PPARg, or any
other kinase, the probe does not interfere with phosphorylation
of other substrates in the proteome.
In mice fed a high-fat diet, ML244 reduced Cdk5-mediated
phosphorylation of S273 on PPARg, normalized serum glucose
levels, and improved insulin sensitivity. In the leptin-deficient
ob/ob mouse model of severe obesity, ML244 reduced S273
PPARg phosphorylation and improved glucose tolerance
as effectively as rosiglitazone. However unlike rosiglitazone,
ML244 did not cause weight gain or fluid retention in these
mice or reduce bone-cell mineralization in culture. Ongoing
efforts are now focusing on increasing the drug-like properties
of the ML244 scaffold and testing the impact of the resultingcompounds following once-a-day oral administration in obese
mice.
Allosteric Modulators of Muscarinic Receptors
About 30% of currently marketed drugs modulate GPCRs. The
vast majority of GPCR-targeted therapeutics act at an orthos-
teric site, These direct-acting ligands can have a number of po-
tential drawbacks, including inducing toxicity and receptor
desensitization or internalization. In addition, identifying selec-
tive orthosteric ligands has often been difficult (Conn et al.,
2009a). Muscarinic acetylcholine receptors (mAChRs) have at-
tracted significant interest as therapeutic targets in multiple
neurological disorders. In Phase II and Phase III clinical trials,
pan-orthosteric agonists of the five humanmAChRs led to cogni-
tive improvements and had anti-psychotic effects in Alzheimer
disease (AD) and schizophrenia. However, adverse events,
which were believed to result from activation of the M2 mAChR
andM3mAChR in the periphery, prevented further clinical devel-
opment of the compounds. Despite significant effort, selectively
targeting the acetylcholine-binding site of the mAchRs did not
prove possible (Conn et al., 2009b) due to the high evolutionary
conservation across subtypes for the endogenous acetylcholine
ligand.
In contrast, allosteric sites are less evolutionarily conserved
across receptor subtypes and have afforded exciting opportu-
nities to achieve true subtype selectivity, as well as diverse phar-
macology by stabilizing unique, activated conformations of the
receptors. Moreover, allosteric sites are generally lipophilic
pockets, which could targeted by unique small-molecule che-
motypes that are structurally distinct from endogenous ligands
(Conn et al., 2009b; Wenthur et al., 2014). With this in mind,
theMLP undertook screening efforts to identify selective positive
allosteric modulators (PAMs) of mAChRs that could be used to
dissect the individual contributions of these receptors to the
therapeutic efficacy of pan-mAChR agonists. These efforts
were aided by using functional assays that enabled the identifi-
cation of PAMs and negative allosteric modulators (NAMs) in a
single kinetic calcium assay. While the HTS afforded hits, these
compounds did not have the physiochemical properties and
CNS penetration needed for in vivo target validation experi-
ments. Achieving high-quality small-molecule probes required
significant medicinal chemistry optimization of the initial
screening hits, leading to the identification of an M1-selective
PAM (ML169; Figure 3) (Bridges et al., 2010; Reid et al., 2011;
Tarr et al., 2012), an M4-selective PAM (ML253; Figure 3) (Le
et al., 2013; Niswender et al., 2010), and an M5-selective PAM
(ML326; Figure 3) (Gentry et al., 2010; Gentry et al., 2013). All
of these probes had submicromolar EC50s, at least 10-fold
selectivity over the other receptor subtypes and, importantly,
were brain penetrant.
In a mouse model of an aspect of AD, the M1-selective probe
ML169 potentiated chemically induced excitation in the striatum,
which is believed to mediate anti-psychotic effects, and favored
the production of soluble, rather than amyloid, APP (Tarr et al.,
2012). In a mouse model of psychiatric disorders, M4-selective
ML253 reversed amphetamine-induced hyperlocomotion, reca-
pitulating the effects of known anti-psychotic agents (Le et al.,
2013). Further experiments are now focusing on using these
probes to explore the biology andpotential therapeutic relevanceCell 161, June 4, 2015 ª2015 Elsevier Inc. 1259
of these receptors, including investigating the role of M5, about
which little is currently known.
Small-Molecule Activators of a Metabolic Enzyme
Tumor growth is associated with metabolic adaptations that
facilitate cell-autonomous nutrient uptake, an increased rate of
aerobic glycolysis, and a shift toward more anabolic metabolism
to support cancer cell growth and proliferation. Emerging mech-
anistic insights into how metabolic pathways are regulated in
cancer are pointing toward potential new therapeutic targets;
however, which targets represent true cancer dependencies
versus nodes where metabolic plasticity will allow cancer cells
to adapt and to escape metabolism-targeting therapeutics re-
mains an open question. Small-molecule probes are urgently
needed to study how metabolism is altered to support tumor
growth and to identify cancer metabolism targets that could be
exploited therapeutically.
Cancer cells in general adopt a less differentiated cell state
and, analogous to less differentiated non-cancerous cells (e.g.,
adult stem cells), tend to rely on aerobic glycolysis. Pyruvate
kinase, which catalyzes the final step in glycolysis, is derived
from two gene products that each possesses two alternate
splice isoforms. Cancer cells often express the M2 isozyme of
pyruvate kinase (PKM2), which promotes aerobic glycolysis. In
contrast, the M1 isozyme (PKM1) promotes glucose oxidation
and is expressed in tissues with high ATP requirements such
as muscle, heart, and brain. The level of regulation of these iso-
zymes is highly divergent. PKM1 has high constitutive activity,
whereas PKM2 can adopt an active or inactive conformation in
response to signaling inputs. PKM1 expression increases oxida-
tive glucose metabolism and can suppress both cell proliferation
and tumor growth (Christofk et al., 2008; Israelsen et al., 2013;
Lunt et al., 2015). However, the extent to which ectopic PKM1
expression recapitulates small-molecule activation of PKM2
was unknown, leaving uncertain whether small-molecule modu-
lation of PKM2 activity would lead to changes in tumor growth or
viability.
More rigorously testing the potential of this therapeutic
approach and better understanding the role of pyruvate kinase
activity in cancer biology required small-molecule activators of
PKM2, yet activating protein function is considered a tall order
for small molecules. To address this gap, the MLP conducted
a screen to identify molecules that increased PKM2 activity in
a biochemical assay. Three different chemotypes were identified
and confirmed to be bona fide activators of PKM2. Subsequent
optimization of these hits resulted in the identification of ML203
(DASA-58; Figure 3) andML265 (TEPP-46; Figure 3), the first two
reported PKM2 activators (Boxer et al., 2010). Further character-
ization demonstrated that the probes increase activity by stabi-
lizing formation of the PKM2 tetramer, the more active form of
the enzyme. This tetramer stabilization is further enhanced in
the presence of fructose-1,6-bisphosphate (FBP), an endoge-
nous activator of PKM2. Structural studies revealed that the
synthetic small-molecule activators occupy a binding site at a
monomer-monomer interface distinct from the allosteric site
bound by FBP (Anastasiou et al., 2012). Thus, these MLP probes
enhance enzyme activity by stabilizing a protein-protein interac-
tion—a mechanism of action generally viewed as challenging to
accomplish (Thiel et al., 2012).1260 Cell 161, June 4, 2015 ª2015 Elsevier Inc.Next, the probes were used to explore the cancer contexts in
which activating PKM2 might provide a therapeutic benefit. In
cancer cell lines grown in culture, ML203 and ML265 reduced
cellular proliferation and had an impact on metabolite levels
distinct from the changes observed with ectopic PKM2 expres-
sion (Anastasiou et al., 2012). A change in serinemetabolismwas
among the most dramatic changes observed, and PKM2 activa-
tion can synergize with serine deprivation to slow the growth of
cancer cells (Kung et al., 2012). Pyruvate kinase activation can
also impair the growth of xenograft tumors with oral dosing of
ML265 causing increased tumor latency and reduced tumor
size (Anastasiou et al., 2012). Although these results provide
initial evidence that activating PKM2 is tumor suppressive, the
effect was relatively modest and the molecules had the highest
efficacy in slowing tumor initiation.
A critical next step will be determining if there are established
tumor contexts that are particularly dependent on low PK
activity or if there are combination treatments that confer
particular sensitivity to PKM2 activation, for instance modula-
tors of serine metabolism. Beyond its role in tumors, regulated
PK activity is also found in non-cancerous tissues, including the
liver and red blood cells. Thus, activation of PKM2 or another
PK isoform using small molecules could be beneficial in both
cancer and non-cancer disease states. To this end, PK activa-
tors are currently being explored as therapeutics for pyruvate
kinase deficiency, an inborn error of metabolism that specif-
ically affects the red blood cell isoform of PK (Zanella et al.,
2007).
Stabilizing a Folded Lysosomal Enzyme While Retaining
Its Activity
Gaucher disease is a rare, autosomal disorder that results
from a deficiency in the lysosomal enzyme glucocerebrosidase
(GCase). Currently, approved treatments for the disease include
enzyme-replacement therapy, which is effective for some pa-
tients who have themost common form of the disease; however,
it is also expensive (Ortolano et al., 2014). When enzyme-
replacement therapy is not an option, patients may be treated
with a small-molecule inhibitor of glucosylceramide synthetase,
decreasing production of glucocerebrosides, the substrate of
GCase that accumulates in disease. This therapy is associated
with a number of side effects including weight loss, tremors,
and peripheral nerve damage (Larsen et al., 2012). Neither of
these treatments is effective against neuropathic forms of the
disease (Suzuki, 2013).
Many GCase mutants found in Gaucher’s patients are enzy-
matically active but are improperly folded by ER chaperone
proteins, causing ER accumulation and degradation before the
protein reaches the lysosome (Orvisky et al., 2002). As a result,
current drug-discovery efforts are focusing on identifying chem-
ical chaperones that bind mutant GCase to increase the fraction
of properly folded enzyme and promote greater trafficking to the
lysosome. Chemical chaperones identified to date are transition-
state mimetics that stabilize the enzyme, but also inhibit enzy-
matic activity (Suzuki, 2013). The most advanced chemical
GCase chaperone, isofagomine, was recently tested in Phase
II clinical trials. Isofagomine increased GCase levels in the white
blood cells of all patients treated, demonstrating its capacity to
increase trafficking. However, the treatment only led to a clinical
improvement in one of 18 patients who completed the study,
probably due to isofagomine’s inhibition of GCase activity (Pan-
icker et al., 2012).
Chemical chaperones that stabilize the enzyme without
inhibiting activity may provide a therapeutic approach with
improved efficacy. To identify such compounds, the MLP
developed a high throughput dose-response assay that used
a spleen homogenate solution from a patient with Gaucher’s
disease, thus creating an assay using mutant enzyme in a
physiological environment. This assay enabled the identifica-
tion of a pyrazolopyrimidine-based molecule that was opti-
mized to the small-molecule probe ML198 (Figure 3) (Goldin
et al., 2012; Rogers et al., 2010). In three patient-derived
dermal fibroblast lines with distinct genotypes, ML198
increased the activity and lysosomal localization of mutant
GCase. Moreover, in macrophages from Gaucher’s patients,
ML198 reduced aberrant lipid accumulation and normalized
phagocytic and efferocytosis function. The MLP probe also dis-
played good pharmacokinetics and brain penetration in mice
(Patnaik et al., 2012).
Innovating Small-Molecule Discovery
Human biology is providing new insights into therapeutic tar-
gets. For example, human genetics is revealing risk and protec-
tive variants of genes across a range of diseases. Biochemical
investigations of variant proteins can provide a blueprint or
recipe to follow that defines the activity that a drug should
confer on the more common version of the protein. However,
the activities suggested by these ‘‘experiments of nature’’
(Plenge et al., 2013) are challenging and generally unfamiliar
to historical drug discovery. For example, rather than pointing
to the need for inhibiting a specific protein kinase, they might
highlight the need for stabilizing a specific protein such as
APP or ApoE to reduce levels of a post-translational modifica-
tion (Jonsson et al., 2012; Mahley and Huang, 2012). Drugs do
not yet exist that have these mechanisms of action. To realize
the promise of precision medicine there is a great need to inno-
vate chemistry, chemical biology, and other areas of science
and engineering related to therapeutics discovery if we are to
uncover the kinds of mechanism of action compounds sug-
gested by human biology.
TheMLP has been an early pioneer in efforts to develop small-
molecule probes with novel mechanisms of action. One of the
lessons learned was the power of close collaborations of aca-
demic biologists and clinicians with chemists and chemical
biologists for developing effective and informative probes that
facilitate studies of emerging biology. Another insight gained
was the critical importance of devoting sufficient resources to
chemical optimization. Hits straight from screens rarely have
the potency and selectivity necessary to be effective tool com-
pounds—and if used with insufficient caution can lead to non-
robust conclusions (Begley and Ellis, 2012). Some percentage
of hits identified in screens are likely promiscuous compounds
unlikely to ever yield tool compounds (Baell and Walters,
2014). Other hits are good starting points, but require a substan-
tial investment in ‘‘hit-to-probe’’ chemistry. When this invest-
ment is made, the resulting compounds can provide unique
avenues for exploring biology. For instance, theMLP has discov-ered many small-molecule probes that modulate targets via
mechanisms that are difficult or impossible to explore by
genetic perturbations, such as altering the rate of protein modi-
fications (noted above), disrupting protein-protein interactions,
increasing protein stability, and inhibiting protein dimerization
(Figure S1).
The MLP has not been alone in recognizing the critical exper-
imental niche filled by small-molecule probes (Edwards et al.,
2015; Edwards et al., 2011; Frye, 2010; Workman and Collins,
2010). Numerous academic and industrial efforts, including
public-private partnerships such as the one led by the Structural
Genomics Consortium, now focus on identifying and publishing
potent and selective small molecules. As a result, the use of
small-molecule probes has become a more established part of
the biologist’s toolkit.
Once high-quality small-molecule probes are developed, one
of the biggest current hurdles to translation is that preclinical
models do not accurately predict efficacy and toxicity in hu-
mans. Academically initiated human experiments, for example,
involving Phase 0 (the FDA exploratory IND path) or Phase I
trials—if performed with safe compounds—could be used to
look for target engagement and the modulation of biomarkers
likely to be predictive of efficacy. Testing disease hypotheses
emerging from human biology with on-mechanism small mole-
cules in humans, although insufficient for drug approval, would
almost certainly increase the probability of successful drug
development and eventual approval.
In addition to enabling advances in biological understanding,
small-molecule probes are more directly impacting therapeutic
discovery. For instance, in multiple cases, biotechnology or
pharmaceutical companies have licensed the intellectual prop-
erty around MLP probes (Table 1). This investment speaks to
the potential for academic small-molecule probe discovery to
impact drug discovery efforts. However, there remains an alarm-
ing disconnect between the pace at which potential therapeutic
targets are uncovered and our ability to develop small molecules
with the desired activity.
In contrast to a decade ago, the infrastructure and expertise
for small-molecule discovery is firmly rooted in academic set-
tings. Innovative small-molecule science is now embedded in
academia alongside deep and rapidly advancing biomedical
knowledge (Reed et al., 2012). Advancing small-molecule dis-
covery in this environment, particularly when methods, data,
and small-molecule probes are made openly available, may pro-
vide an effective bridge toward more rapidly identifying small
molecules that modulate the challenging mechanisms illumi-
nated by human biology to accelerate the testing of emerging
therapeutic hypotheses.
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